1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Alcala S, Serralta San Martin G, Muñoz-Fernández de Legaria M, Moreno-Rubio J, Salinas S, López-Gil JC, Rojo López JA, Martínez Alegre J, Cortes Bandy DA, Zambrana F, Jiménez-Gordo AM, Casado E, López-Gómez M, Sainz B.

    Autofluorescent Cancer Stem Cells: Potential Biomarker to Predict Recurrence in Resected Colorectal Tumors.

    Cancer Research Communications . 4(10): 2575-2588.

    [doi:10.1158/2767-9764.CRC-24-0188]

  • Chung HC, Saada-Bouzid E, Longo F, Yanez E, Im SA, Castanon E, Desautels DN, Graham DM, Garcia-Corbacho J, Lopez J, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Korakis I.

    Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.

    CANCER . 130(19): 3278-3288.

    [doi:10.1002/cncr.35387]

  • Budillon A, Leone A, Passaro E, Silvestro L, Foschini F, Iannelli F, Roca MS, Macchini M, Bruzzese F, Garcia Bermejo ML, Rodriguez Garrote M, Tortora G, Milella M, Reni M, Fuchs C, Hewitt E, Kubiak C, Di Gennaro E, Giannarelli D, Avallone A.

    Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.

    Bmc Cancer . 24(1): 1167-1167.

    [doi:10.1186/s12885-024-12936-w]

  • Niedra, Helvijs, Peculis, Raitis, Saksis, Rihards, Mandrika, Ilona, Vilisova, Sofija, Nazarovs, Jurijs, Breiksa, Austra, Gerina, Aija, Earl, Julie, Ruz-Caracuel, Ignacio, Rosas, Marta Gabriela, Pukitis, Aldis, Senterjakova, Natalja, Rovite, Vita.

    Tumor and a-SMA-expressing stromal cells in pancreatic neuroendocrine tumors have a distinct RNA profile depending on tumor grade

    MOLECULAR ONCOLOGY . : .

    [doi:10.1002/1878-0261.13727]

  • Mirasierra M, Fernández-Pérez A, Lizarbe B, Keiran N, Ruiz-Cañas L, Casarejos MJ, Cerdán S, Vendrell J, Fernández-Veledo S, Vallejo M.

    Alx3 deficiency disrupts energy homeostasis, alters body composition, and impairs hypothalamic regulation of food intake.

    CELLULAR AND MOLECULAR LIFE SCIENCES . 81(1): 343-343.

    [doi:10.1007/s00018-024-05384-z]

  • Albarrán V, Guerrero P, de Quevedo CG, González C, Chamorro J, Rosero DI, Moreno J, Calvo JC, de Aguado PP, Alía V, Sotoca P, Barrill AM, Román MS, Álvarez-Ballesteros P, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Garrido P, Gajate P.

    Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 73(10): 186-186.

    [doi:10.1007/s00262-024-03772-9]

  • Melones-Herrero J, Delgado-Aliseda P, Figueiras S, Velázquez-Gutiérrez J, Quiroga AG, Calés C, Sánchez-Pérez I.

    Trans-[Pt(amine)Cl(2)(PPh(3))] Complexes Target Mitochondria and Endoplasmic Reticulum in Gastric Cancer Cells.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(14): .

    [doi:10.3390/ijms25147739]

  • Moreno-Cabrera JM, Feliubadaló L, Pineda M, Prada-Dacasa P, Ramos-Muntada M, Del Valle J, Brunet J, Gel B, Currás-Freixes M, Calsina B, Salazar-Hidalgo ME, Rodríguez-Balada M, Roig B, Fernández-Castillejo S, Durán Domínguez M, Arranz Ledo M, Infante Sanz M, Castillejo A, Dámaso E, Soto JL, de Miguel M, Hidalgo Calero B, Sánchez-Zapardiel JM, Ramon Y Cajal T, Lasa A, Gisbert-Beamud A, López-Novo A, Ruiz-Ponte C, Potrony M, Álvarez-Mora MI, Osorio A, Lorda-Sánchez I, Robledo M, Cascón A, Ruiz A, Spataro N, Hernan I, Borràs E, Moles-Fernández A, Earl J, Cadiñanos J, Sánchez-Heras AB, Bigas A, Capellá G, Lázaro C.

    SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population.

    DATABASE-OXFORD . 2024: .

    [doi:10.1093/database/baae055]

  • Van Laethem JL, Borbath I, Prenen H, Geboes KP, Lambert A, Mitry E, Cassier PA, Blanc JF, Pilla L, Batlle JF, Garrote MR, Pazo-Cid RA, Gallego I, Smith KE, Ellmark P, Pico de Coaña Y, Ambarkhane SV, Macarulla T.

    Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.

    LANCET ONCOLOGY . 25(7): 853-864.

    [doi:10.1016/S1470-2045(24)00263-8]

  • Juez LD, Priego P, Cuadrado M, Blázquez LA, Sánchez-Picot S, Gil P, Longo F, Galindo J, Fernández-Cebrián JM, Botella-Carretero JI.

    Impact of Neoadjuvant Treatment on Body Composition in Patients with Locally Advanced Gastric Cancer.

    Cancers . 16(13): .

    [doi:10.3390/cancers16132408]

  • Ibello E, Saracino F, Delle Cave D, Buonaiuto S, Amoroso F, Andolfi G, Corona M, Guardiola O, Colonna V, Sainz B Jr, Altucci L, De Cesare D, Cobellis G, Lonardo E, Patriarca EJ, D'Aniello C, Minchiotti G.

    Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism.

    Journal Of Experimental & Clinical Cancer Research . 43(1): 165-165.

    [doi:10.1186/s13046-024-03072-1]

  • Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C.

    Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).

    JOURNAL OF NEURO-ONCOLOGY . 168(2): 299-306.

    [doi:10.1007/s11060-024-04668-5]

  • Moura DS, Mondaza-Hernandez JL, Sanchez-Bustos P, Peña-Chilet M, Cordero-Varela JA, Lopez-Alvarez M, Carrillo-Garcia J, Martin-Ruiz M, Romero-Gonzalez P, Renshaw-Calderon M, Ramos R, Marcilla D, Alvarez-Alegret R, Agra-Pujol C, Izquierdo F, Ortega-Medina L, Martin-Davila F, Hernandez-Leon CN, Romagosa C, Salgado MAV, Lavernia J, Bagué S, Mayodormo-Aranda E, Alvarez R, Valverde C, Martinez-Trufero J, Castilla-Ramirez C, Gutierrez A, Dopazo J, Hindi N, Garcia-Foncillas J, Martin-Broto J.

    HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.

    CELLULAR AND MOLECULAR LIFE SCIENCES . 81(1): 219-219.

    [doi:10.1007/s00018-024-05250-y]

  • Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V, Moreno V.

    Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.

    Clinical cancer research : an official journal of the American Association for Cancer Research . : .

    [doi:10.1158/1078-0432.CCR-23-2677]

  • Cristina-Marianini-Rios, Sanchez MEC, de Paredes AGG, Rodríguez M, Barreto E, López JV, Fuentes R, Beltrán MM, Sanjuanbenito A, Lobo E, Caminoa A, Ruz-Caracuel I, Durán SL, Olcina JRF, Blázquez J, Sequeros EV, Carrato A, Ávila JCM, Earl J.

    The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no known pathogenic germline variants.

    FAMILIAL CANCER . : . Nº de citas: 1

    [doi:10.1007/s10689-024-00397-w]

  • Earl J, Fuentes R, Sanchez MEC, de Paredes AGG, Muñoz M, Sanjuanbenito A, Lobo E, Caminoa A, Rodríguez M, Barreto E, López JV, Ruz-Caracuel I, Durán SL, Olcina JRF, Sánchez BL, Páez SC, Torres A, Blázquez J, Sequeros EV, Carrato A.

    The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer.

    FAMILIAL CANCER . : . Nº de citas: 1

    [doi:10.1007/s10689-024-00388-x]

  • Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, Berciano-Guerrero MÁ, Cerezuela P, Martin-Liberal J, Muñoz-Couselo E, Espinosa E, Drozdowskyj A, Berrocal A, Soria A, Marquez-Rodas I, Martin-Algarra S, Quindos M, Puig S.

    Access to melanoma drugs in Spain: a cross-sectional survey.

    CLINICAL & TRANSLATIONAL ONCOLOGY . : . Nº de citas: 1

    [doi:10.1007/s12094-024-03501-9]

  • López-Gil JC, García-Silva S, Ruiz-Cañas L, Navarro D, Palencia-Campos A, Giráldez-Trujillo A, Earl J, Dorado J, Gómez-López G, Monfort-Vengut A, Alcalá S, Gaida MM, García-Mulero S, Cabezas-Sáinz P, Batres-Ramos S, Barreto E, Sánchez-Tomero P, Vallespinós M, Ambler L, Lin ML, Aicher A, García García de Paredes A, de la Pinta C, Sanjuanbenito A, Ruz-Caracuel I, Rodríguez-Garrote M, Guerra C, Carrato A, de Cárcer G, Sánchez L, Nombela-Arrieta C, Espinet E, Sanchez-Arevalo Lobo VJ, Heeschen C, Sainz B Jr.

    The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.

    Gut . : .

    [doi:10.1136/gutjnl-2023-330995]